S&H partners with Proscape Technologies

Share this article:

Avenue-e Health Strategies, the e-marketing division of Sudler & Hennessey, has formed a partnership with Proscape Technologies, the leading provider of interactive selling platforms.
Proscape is an established expert in a new breed of technology-based solutions, Marketing and Sales Effectiveness (MSE), which bridges marketing and sales to heighten selling effectiveness.
Now as an "authorized business partner" of Proscape, Avenue-e Health Strategies can deliver more effective digital detailing solutions for the Tablet PC, such as strategic setup, success criteria, implementation and rollout, and testing methodologies. By being authorized to develop and manage content for the Proscape system, Avenue-e can provide solutions that empower sales forces and make selling simpler.
"S&H and its e-marketing group, Avenue-e, are known as experts in developing professional promotion and interactive programs for top pharmaceutical companies," stated Anthony Manson, senior vice president and managing director of Avenue-e. "As with any new medium or device, it might look cool, but can the content attract and engage a healthcare physician?  Realizing the full potential of this new technology involves more than simply scanning a paper document and putting it on a PC tablet. It's about finding the right strategy and combining it with  multi-media tools to tell a powerful story--that ultimately makes the rep's job easier. The partnership of Avenue-e and Proscape Technologies, two cutting-edge companies, makes this all possible."

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.